SloveniaZuellig Pharma, a major healthcare company in Asia, has acquired all rights to Cialis® (Tadalafil) from Eli Lilly and Company in Singapore. This acquisition grants Zuellig Pharma control over the trademarks, marketing authorizations, and manufacturing know-how for Cialis®, which treats erectile dysfunction (ED) and benign prostatic hyperplasia (BPH). The deal expands Zuellig Pharma’s presence in 12 Asian markets and enhances access to the medication for men affected by these conditions. The company emphasized that this move supports its strategy of developing a robust portfolio of healthcare products and improving healthcare accessibility across Asia.
Bias read (Center): The article presents the acquisition as a business development and strategic move, focusing on corporate goals such as expanding market reach and enhancing healthcare accessibility. There is no overt ideological framing or emphasis on political implications. The tone remains neutral, highlighting Zu
